Altre lingue Voyageur Pharmaceuticals Ltd. Toronto S.E.

Azioni

VM

CA92916K1057

Tempo differito Toronto S.E. Altri mercati azionari			Variaz. 5gg	Var. 1 gen.
- ^CAD	-.--%		+7,14%	-.--%

11/06	Voyageur Pharmaceuticals Ltd. e Rain Cage Carbon Inc. annunciano il seguito della prima creazione commerciale del Fullerene Endoedrico V@C60	CI
28/05	Voyageur Pharmaceuticals Ltd ottiene un contratto di vendita da 1,9 milioni di dollari per il contrasto al bario SmoothXTM al 2%.	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Voyageur Pharmaceuticals Grants Deferred Share Units	09/07
Voyageur Pharmaceuticals and Rain Cage Carbon Partner to Develop Advanced Radiology Contrast Agents	11/06
Voyageur Pharmaceuticals Ltd. and Rain Cage Carbon Inc. Announce Follow Up on the First Commercial Creation of V@C60 Endohedral Fullerene	11/06
Testing to Begin of Radiology Endohedral Fullerenes, a Milestone in Nanotechnology & Drug Development	11/06
Voyageur Pharmaceuticals Secures $1.9 Million Sales Contract for Latin America	28/05
Voyageur Pharmaceuticals Ltd Secures USD 1.9 Million Sales Contract for SmoothXTM 2% Barium Contrast	28/05
Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast	28/05
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 29, 2024	26/04
Voyageur Pharmaceuticals Ltd Grants Deferred Share Units Compensation to Independent Directors	03/04
Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options	26/03
Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2023	26/03
Voyageur Pharmaceuticals Ltd. Announces A Significant Advancement in Its Partnership with Rain Cage Carbon Inc	13/03
Voyageur Achieves Milestone with Rain Cage Royalty Agreement for Sustainable Carbon Drug Development	13/03
Voyageur Pharmaceuticals Ltd. and Applied Pharmaceutical Innovation Sign Master Services Agreement	04/03
Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement	04/03
Voyageur Pharmaceuticals Ltd. Announces Closing of Private Placement	01/03
Voyageur Pharmaceuticals Ltd. announced that it has received CAD 0.4885 million in funding	01/03
Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 0.8 million in funding	16/01
Voyageur Pharmaceuticals Ltd Announces Deferred Share Unit (DSU) Grant to Directors	21/12
Voyageur Pharmaceuticals Ltd and Rain Cage Carbon Inc, Announce Breakthrough in Imaging Technology with Vanadium Fullerene Molecule	21/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Voyageur Pharmaceuticals Ltd. Toronto S.E.

Azioni

VM

CA92916K1057

Altre lingue

Filtri